Claritev Corporation (NYSE: CTEV), formerly known as MultiPlan Corporation, is a healthcare technology and data-analytics company. It provides payment integrity, cost management, network, and data-driven solutions to commercial health insurers, employers, third-party administrators, and other participants in the U.S. claims adjudication process. The company was rebranded in February 2025 and is headquartered in McLean, Virginia.
Claritev has long been a dominant processor of out-of-network healthcare claims, and its new leadership team has been working since 2024 on a turnaround focused on expanding the customer base, cross-selling additional products, and entering new markets.
Shares closed near $37.57 on August 26, 2026, giving the company a market capitalization of roughly $637 million. That relatively small equity value, however, sits atop a much larger enterprise value of about $5.3 billion, reflecting a debt load in the range of $4.7 billion. In other words, the equity is highly leveraged, which magnifies both the upside and the downside of any share-price move.
The stock has experienced extraordinary swings. Its 52-week range spans from a low of $11.50 to a high of $74.07. After a steep decline in the first half of 2026, shares staged a powerful recovery, gaining roughly 70% in a single month. A move to $50 would represent a further gain of about 33% from current levels — significant, but still well below the stock's prior peak.
Several factors support the case for a continued climb toward $50. Second-quarter 2026 revenue rose 6.6% year over year to $257.5 million, and management raised its full-year revenue outlook to between $1.0 billion and $1.02 billion, while lifting its adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance to $610–$620 million.
Bookings momentum has also improved. The company reported $30 million in annual contract value during the second quarter and $74 million in the first half, with a stated goal of exceeding $100 million for the full year. Analysts have pointed to new customer wins, multi-year renewals, international expansion into regions such as the Middle East, and investments in artificial intelligence and cloud migration as potential long-term growth drivers.
The primary obstacle is the balance sheet. Claritev remains unprofitable on a generally accepted accounting principles (GAAP) basis, reporting a net loss of $59.2 million in the second quarter and a trailing EPS (earnings per share) of roughly -$17.00. With debt representing the vast majority of total capital, deleveraging remains a slow process, and higher interest costs weigh on earnings power.
The company is also heavily dependent on a core group of payor and third-party administrator clients, exposing it to healthcare policy shifts, reimbursement changes, and growing competition from larger technology-focused entrants. Antitrust and regulatory scrutiny around out-of-network pricing have been recurring concerns, and any adverse headlines could quickly reverse sentiment in a stock this volatile.
Wall Street's view is generally constructive but far from uniform. The consensus rating is a "Buy," with an average 12-month price target of roughly $43 to $46. Recent adjustments reflect the improving outlook: Canaccord raised its target to $43, Citi to $45, Barclays to $40, and Wells Fargo to $30. At the bullish end, Piper Sandler carries a $73 target, while the most cautious estimates sit in the $28–$30 range.
This spread matters for the $50 question. The consensus target sits just below $50, meaning the market's "average" expectation falls slightly short of the goal. Reaching $50 would likely require the company to convert its improving bookings into sustained, profitable growth — enough to persuade the Street that a higher valuation multiple is justified.
Traders monitoring fast-moving, volatile names such as Claritev may also find value in automated market tools. AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and identify shifting market trends more efficiently. For those following Claritev's sharp swings, these signals offer a neutral, data-driven complement to traditional technical and fundamental research.
A move to $50 from roughly $37.57 is ambitious but not unrealistic. The strongest arguments in favor are the stock's recent momentum, rising revenue, improving bookings, and a series of higher analyst targets — all of which suggest the turnaround narrative still has room to run. At the same time, $50 sits slightly above the Street's consensus target, and the path there depends on consistent execution, progress toward profitability, and successful deleveraging.
The primary risks are clear: a leveraged balance sheet, ongoing GAAP losses, client concentration, and regulatory exposure. Investors weighing whether Claritev can reach $50 should watch revenue and EBITDA guidance, quarterly bookings, any changes to the debt structure, and whether the stock can hold above its recent support near $30 while building toward higher levels. No outcome is guaranteed, and the stock's extreme volatility means both scenarios remain firmly on the table.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CTEV has been loosely correlated with COMP. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CTEV jumps, then COMP could also see price increases.
| Ticker / NAME | Correlation To CTEV | 1D Price Change % | ||
|---|---|---|---|---|
| CTEV | 100% | -2.07% | ||
| COMP - CTEV | 36% Loosely correlated | +3.75% | ||
| CLSK - CTEV | 36% Loosely correlated | +6.80% | ||
| RIOT - CTEV | 34% Loosely correlated | +2.48% | ||
| COIN - CTEV | 32% Poorly correlated | +1.73% | ||
| TGL - CTEV | 30% Poorly correlated | -8.39% | ||
More | ||||
| Ticker / NAME | Correlation To CTEV | 1D Price Change % |
|---|---|---|
| CTEV | 100% | -2.07% |
| Services to the Health Industry industry (42 stocks) | 9% Poorly correlated | +0.43% |
| Health Services industry (242 stocks) | -0% Poorly correlated | +0.38% |